This phase 1 study (NCT05463952) aimed to investigate the safety, pharmacokinetics, and preliminary efficacy of vepdegestrant in Japanese patients with ER+/HER2- advanced breast cancer at the recommended phase 3 dose (RP3D) of 200 mg QD. This evidence concerns the gene ESR1 and breast carcinoma.